make a ppt of 5 slides for Brief background of the research area and current scenario. • Identify the research gap and unmet need. • Significance of the study in advancing knowledge. • Relevance to healthcare, society and institutional priorities using the following summary Human Interleukin-2 is an important cytokine, plays an important role in activating the signalling pathways of immune responses particularly in sustaining the proliferation, effector function, and persistence of T-cells (1, 2,3) IL-2 has emerged as a crucial component for supporting the expansion and antitumor efficacy of CAR engineered T-cells. Despite its immense therapeutic potential, the clinical application of recombinant human IL-2 (rhIL-2) is significantly hindered by substantial manufacturing and procurement bottlenecks (4,5,2). The exacerbate supply chain instability of hrIL2 causes the CAR T cell therapy expensive. Addressing the constraint through the development of indigenous, cost-effective microbial expression platform is therefore critical to reducing the financial burden of CAR T-cell therapies, Currently, no universal or standardized platform exists for the cost-effective production of recombinant human IL-2; rather, efforts are focused on fragmented optimization strategies, often involving genetically engineered Escherichia coli strains designed to enhance expression. Furthermore, the incorporation of various fusion tags is frequently utilized to mitigate the formation of insoluble aggregates, thereby enhancing protein solubility and facilitating streamlined purification workflows that require minimal processing steps (6,7,8,9). To develop a cost-effective and scalable rhIL-2 production platform, this study will systematically compare three affinity/solubility tags and three Escherichia coli expression hosts. The 6×His tag offers economical IMAC purification with minimal impact on protein folding. The 6×His-SUMO tag has consistently demonstrated among the highest reported yields of soluble recombinant proteins, including rhIL-2, owing to its superior enhancement of protein folding and solubility (10). The 6HFh8 tag, which has shown improved soluble expression and yield for several recombinant growth factors, has not been extensively explored for rhIL-2 production, providing a strong rationale to evaluate its potential(11). BL21(DE3), Origami (DE3), and Rosetta-gami 2(DE3) will be compared to identify the optimal host–tag combination for high-yield, biologically active, and economically viable rhIL-2 production under optimized culture conditions. .
make a ppt of 5 slides for Brief background of the research area and current scenario.
• Identify the research gap and unmet need.
• Significance of the study in advancing knowledge.
• Relevance to healthcare, society and institutional priorities using the following summary Human Interleukin-2 is an important cytokine, plays an important role in activating the signalling pathways of immune responses particularly in sustaining the proliferation, effector function, and persistence of T-cells (1, 2,3) IL-2 has emerged as a crucial component for supporting the expansion and antitumor efficacy of CAR engineered T-cells. Despite its immense therapeutic potential, the clinical application of recombinant human IL-2 (rhIL-2) is significantly hindered by substantial manufacturing and procurement bottlenecks (4,5,2). The exacerbate supply chain instability of hrIL2 causes the CAR T cell therapy expensive. Addressing the constraint through the development of indigenous, cost-effective microbial expression platform is therefore critical to reducing the financial burden of CAR T-cell therapies,
Currently, no universal or standardized platform exists for the cost-effective production of recombinant human IL-2; rather, efforts are focused on fragmented optimization strategies, often involving genetically engineered Escherichia coli strains designed to enhance expression. Furthermore, the incorporation of various fusion tags is frequently utilized to mitigate the formation of insoluble aggregates, thereby enhancing protein solubility and facilitating streamlined purification workflows that require minimal processing steps (6,7,8,9).
To develop a cost-effective and scalable rhIL-2 production platform, this study will systematically compare three affinity/solubility tags and three Escherichia coli expression hosts. The 6×His tag offers economical IMAC purification with minimal impact on protein folding. The 6×His-SUMO tag has consistently demonstrated among the highest reported yields of soluble recombinant proteins, including rhIL-2, owing to its superior enhancement of protein folding and solubility (10). The 6HFh8 tag, which has shown improved soluble expression and yield for several recombinant growth factors, has not been extensively explored for rhIL-2 production, providing a strong rationale to evaluate its potential(11). BL21(DE3), Origami (DE3), and Rosetta-gami 2(DE3) will be compared to identify the optimal host–tag combination for high-yield, biologically active, and economically viable rhIL-2 production under optimized culture conditions.
.
Created using ChatSlide
This project addresses a critical clinical need by exploring the role of IL-2 in T-cell expansion and the challenges posed by supply bottlenecks in CAR-T therapy. It aims to fill the research gap by developing a standard, affordable recombinant IL-2 platform. The proposed platform will compare three tags across different E. coli hosts to assess yield, solubility, and activity trade-offs, ultimately enabling scalable and cost-effective indigenous production.